BofA analyst Jason Gerberry lowered the firm’s price target on Eli Lilly (LLY) to $1,268 from $1,286 and keeps a Buy rating on the shares. The firm, which thinks shares can continue to appreciate as Lilly executes key obesity launches and de-risks new therapies in “nearly every conceivable market segment,” is shifting its valuation basis to its FY27 estimates.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on LLY:
- Eli Lilly & Co: Strategic Initiatives and Promising Market Opportunities Drive Buy Rating
- Eli Lilly’s Mounjaro recommended for extended use by EMA
- Eli Lilly’s New Study on LY3549492: A Potential Breakthrough in Obesity Treatment
- Eli Lilly’s New Study on LY4213663: A Potential Game-Changer for Rheumatoid Arthritis?
- Eli Lilly’s New Study on LY4584180: A Potential Game-Changer in Blood Cancer Treatment?